Kortuc is named as an intervention in 2 current clinical trials in our UK, India and France registers. 1 is recruiting patients now. The most common phase is Phase 1. The sponsor with the most trials is Kortuc, Inc (1). The most-studied condition is Cervical Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01
NCT05570422 · ClinicalTrials.gov ↗ · Cervical Cancer
|
Phase 1 | Recruiting | Kortuc, Inc | UK, India |
|
KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer
NCT07622017 · ClinicalTrials.gov ↗ · Rectal Cancer
|
Phase 2 | Not yet open | Gustave Roussy, Cancer Campus, Grand Paris | France |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Kortuc. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Phase II Clinical Trial of KORTUC (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach (K-BOOST)
2025-524378-40-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Institut Gustave Roussy | France |
| Lead sponsor | Trials |
|---|---|
| Kortuc, Inc | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 1 |
| Clinical trials in India | 1 | 1 |
| Clinical trials in France | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our UK, India and France registers name Kortuc (also registered as KRC-01) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Kortuc, Inc (1) and Gustave Roussy, Cancer Campus, Grand Paris (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Kortuc works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Kortuc works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Kortuc (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.